AUTL
Autolus Therapeutics LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$415.18M
P/E Ratio
—
EPS
$-1.09
Beta
2.00
52W High
$2.70
52W Low
$1.18
50-Day MA
$1.57
200-Day MA
$1.53
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Autolus Therapeutics Ltd
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom.
Fundamentals
| Revenue (TTM) | $1.08M |
| Gross Profit (TTM) | $-26.48M |
| EBITDA | $-68.94M |
| Operating Margin | -6571.00% |
| Return on Equity | -29.60% |
| Return on Assets | -22.30% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $5.91 |
| Price-to-Book | 3.83 |
| Price-to-Sales (TTM) | 384.96 |
| EV/Revenue | 2.883 |
| EV/EBITDA | 0.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 83655.00% |
| Shares Outstanding | $266.14M |
| Float | $33.90M |
| % Insiders | 18.08% |
| % Institutions | 76.21% |
Historical Volatility
HV 10-Day
70.69%
HV 20-Day
80.26%
HV 30-Day
78.55%
HV 60-Day
71.34%
HV Rank
57.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($8.71 target)
1
Strong Buy9
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026